跳至主要内容
临床试验/NL-OMON56396
NL-OMON56396招募中不适用

The safety of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction and the effect on intramyocardial haemorrhage - STOP IMH

Academisch Medisch Centrum0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patients aged 18 years or older are eligible for inclusion if all of the
  • following criteria are met:
  • - Clinical and electrocardiographical diagnosis of ST-elevation myocardial
  • infarction (STEMI)
  • - Successful percutaneous coronary intervention (PCI) of the infarct-related
  • vessel with a modern
  • drug eluting stent (DES)

排除标准

  • - Known allergy or contraindication for aspirin, ticagrelor or prasugrel.
  • - Previous PCI or MI less than 12 months ago
  • - Previous cardiac surgery
  • - Participation in another clinical study with an investigational product
  • - Pregnancy and breast feeding
  • - Concurrent use of oral anticoagulants (OAC)
  • - The periprocedural use of GPIIb/IIIa inhibitors
  • - Planned surgical intervention within 12 months of PCI
  • - Creatinine clearance <30 mL/min or dialysis
  • - PCI of stent thrombosis
  • - Suboptimal stent result as judged by the interventional cardiologist.
  • - Contra-indications for MRI or unable to undergo MRI (only applicable for the
  • CMR subgroup population).

研究者

相似试验

The safety of ticagrelor monotherapy after primary... | 临床试验